vs
Side-by-side financial comparison of Currenc Group Inc. (CURR) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $10.1M, roughly 1.4× Currenc Group Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -46.5%, a 122.2% gap on every dollar of revenue. Currenc Group Inc. produced more free cash flow last quarter ($-1.7M vs $-2.1M).
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
CURR vs XLO — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.1M | $13.7M |
| Net Profit | $-4.7M | $10.4M |
| Gross Margin | 31.8% | — |
| Operating Margin | -43.0% | -86.5% |
| Net Margin | -46.5% | 75.7% |
| Revenue YoY | -23.3% | — |
| Net Profit YoY | -54.0% | 179.1% |
| EPS (diluted) | $-0.13 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.7M | ||
| Q3 25 | — | $19.1M | ||
| Q2 25 | — | $8.1M | ||
| Q1 25 | $10.1M | $2.9M | ||
| Q3 24 | $11.3M | — | ||
| Q1 24 | $13.1M | — | ||
| Q3 23 | $12.7M | — |
| Q4 25 | — | $10.4M | ||
| Q3 25 | — | $-16.3M | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | $-4.7M | $-13.3M | ||
| Q3 24 | $-5.0M | — | ||
| Q1 24 | $-3.0M | — | ||
| Q3 23 | $-3.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 31.8% | — | ||
| Q3 24 | 27.8% | — | ||
| Q1 24 | 33.6% | — | ||
| Q3 23 | 32.5% | — |
| Q4 25 | — | -86.5% | ||
| Q3 25 | — | -10.1% | ||
| Q2 25 | — | -177.7% | ||
| Q1 25 | -43.0% | -472.7% | ||
| Q3 24 | -141.5% | — | ||
| Q1 24 | -10.8% | — | ||
| Q3 23 | -18.2% | — |
| Q4 25 | — | 75.7% | ||
| Q3 25 | — | -85.4% | ||
| Q2 25 | — | -196.0% | ||
| Q1 25 | -46.5% | -452.7% | ||
| Q3 24 | -44.1% | — | ||
| Q1 24 | -23.2% | — | ||
| Q3 23 | -30.1% | — |
| Q4 25 | — | $-3.74 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | $-0.13 | $-0.18 | ||
| Q3 24 | $-0.13 | — | ||
| Q1 24 | $-0.09 | — | ||
| Q3 23 | $-0.11 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $62.3M | $137.5M |
| Total DebtLower is stronger | $3.7M | — |
| Stockholders' EquityBook value | $-68.4M | $35.3M |
| Total Assets | $110.8M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $103.8M | ||
| Q2 25 | — | $121.6M | ||
| Q1 25 | $62.3M | $89.1M | ||
| Q3 24 | $49.1M | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $3.7M | — | ||
| Q3 24 | $20.1M | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | — | $35.3M | ||
| Q3 25 | — | $-8.1M | ||
| Q2 25 | — | $7.1M | ||
| Q1 25 | $-68.4M | $10.7M | ||
| Q3 24 | $-47.0M | — | ||
| Q1 24 | $-10.9M | — | ||
| Q3 23 | $-10.2M | — |
| Q4 25 | — | $154.7M | ||
| Q3 25 | — | $133.7M | ||
| Q2 25 | — | $133.8M | ||
| Q1 25 | $110.8M | $103.7M | ||
| Q3 24 | $115.0M | — | ||
| Q1 24 | $54.5M | — | ||
| Q3 23 | $82.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.5M | $-2.0M |
| Free Cash FlowOCF − Capex | $-1.7M | $-2.1M |
| FCF MarginFCF / Revenue | -16.5% | -15.3% |
| Capex IntensityCapex / Revenue | 1.7% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-17.5M | ||
| Q2 25 | — | $-14.5M | ||
| Q1 25 | $-1.5M | $29.0M | ||
| Q3 24 | $-11.3M | — | ||
| Q1 24 | $-221.0K | — | ||
| Q3 23 | $-10.5M | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | $-1.7M | $29.0M | ||
| Q3 24 | — | — | ||
| Q1 24 | $-233.0K | — | ||
| Q3 23 | — | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | -16.5% | 988.3% | ||
| Q3 24 | — | — | ||
| Q1 24 | -1.8% | — | ||
| Q3 23 | — | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | 1.7% | 0.8% | ||
| Q3 24 | — | — | ||
| Q1 24 | 0.1% | — | ||
| Q3 23 | — | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CURR
| Sales Of Airtime | $5.5M | 54% |
| Fiat Remittance Service | $4.4M | 44% |
XLO
Segment breakdown not available.
